|Articles|June 23, 2005

Medidata 2

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor

February 3rd 2026

SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D

ByRaja Shankar,Andy Studna, Senior Editor

February 3rd 2026

Regulatory Uncertainty Emerges Across the Drug Development Lifecycle

ByCharlie Paterson,Andy Studna, Senior Editor

February 3rd 2026

The industry is witnessing an uptake in the use of the functional-service provider (FSP) model from sponsors who may have been traditionally using the full-service outsourcing model (FSO) model in the past. Credit: Stock.Adobe.com/peopleimages.com.

Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions

ByKerri McCaul-Claus,Allison Covucci

February 3rd 2026

Clinical trials are subject to multiple real-world variables, including varying site competence, patient data variability, changes in the standard of care and fundamental uncertainties about the drug's effect size. Credit: Stock.Adobe.com/photon_photo

De-Risking Development: Prioritizing Robustness in Trial Design

ByElad Berkman

February 2nd 2026

Medidata 2

Newsletter

Related Content

SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations

SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D

Regulatory Uncertainty Emerges Across the Drug Development Lifecycle

Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions

De-Risking Development: Prioritizing Robustness in Trial Design

Trending on Applied Clinical Trials Online

SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D

De-Risking Development: Prioritizing Robustness in Trial Design

Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions

New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN

Regulatory Uncertainty Emerges Across the Drug Development Lifecycle